



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/301,842	04/29/1999	BRIAN C.A. FERNANDES	P0008383.00	6147
27581	7590	09/16/2009		
MEDTRONIC, INC. 710 MEDTRONIC PARKWAY NE MINNEAPOLIS, MN 55432-9924			EXAMINER LAM, ANN Y	
			ART UNIT	PAPER NUMBER
			1641	
			MAIL DATE	DELIVERY MODE
			09/16/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/301,842	Applicant(s) FERNANDES ET AL.	
	Examiner ANN Y. LAM	Art Unit 1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 June 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 21-36, 41-69, 76 and 77 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 21-36, 41-69 is/are allowed.
- 6) ☒ Claim(s) 76 and 77 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 76-77 are rejected under 35 U.S.C. 103(a) as being unpatentable over Helmus et al., 5,447,724, in view of Tweden et al., 5,895,419, and further in view of Fearnot et al., 5,609,629.

Applicant claims a heart valve prosthesis comprising a sewing ring comprising an annular support initially formed from a biostable polymer mixed with a therapeutic agent, said annular support overlaid by a polyester fabric overlay, wherein said annular support provides at least one therapeutic effect to the fabric overlayer.

Helmus disclose polymers which may be used in the formation of or the coating of medical devices which contact body various body tissues and bodily fluids such device being for example, artificial heart components, vascular grafts, heart valves among other things (col. 9, lines 52-68.)

It is also taught by Helmus that the articles might also be formed entirely from the release polymer, in which case, a prepolymer mixture including the desired quantity of heparin is prepared, formed into the desired shape and polymerized. A prepolymer solution containing an elutable component is next applied over the article and polymerized to form the surface-layer. Additionally, articles may be formed by thermal means such as injection molding a mixture of polymer and active agent. The outer layer may be formed by molding the polymer and elutable agent mixture around the body of the device by insert molding techniques (col. 9, lines 38-49.)

Thus, as to claims 21, 45, 46, 52 and 60, Helmus discloses an implantable medical device (see column 9, lines 52-68, disclosing a medical device such as artificial heart components) initially formed from a biostable polymer mixed with a therapeutic agent (see col. 9, lines 38-49, disclosing that the medical device/article may be formed from a prepolymer mixture including the desired quantity of heparin is prepared or alternatively by injection molding a mixture of polymer and active agent), and wherein the medical device comprises a body portion overlaid by a fabric overlayer (see column 9, lines 38-48, disclosing a prepolymer solution containing an elutable component applied over the article and polymerized to form the surface-layer, or alternatively injection molding a mixture of polymer and elutable agent mixture around the body of the device by insert molding techniques), and wherein medical device provides at least one therapeutic effect to the fabric overlayer (see col. 9, 39-40, line 45-46, disclosing the therapeutic agent and col. 3, lines 34-47, and col. 6, lines 18-25, disclosing release of the therapeutic agent.)

However, Helmus does not specifically disclose an embodiment wherein such a medical device is annular or that the medical device includes a polyester fabric overlayer.

Tweden discloses an annuloplasty ring (22) that includes an outer layer of fabric (24), such as a woven or knitted polyester, which may surround a frame (23), which may be flexible, and a polymer, such as silicone (see column 2, lines 45-50, and see column 3, lines 30-33.) Tweden also discloses that the devices could be coated with a therapeutic agent, (see column 2, lines 51-67, see also col. 3, lines 16-19, and col. 4, lines 20-22).

Specifically, Tweden teach that the valved grafts are coated with different pre-clotting agents, such as collagen or gelatin. In this application, the silver coating may underlie the pre-clotting agent, and it is contemplated that silver treatment of only the cuff may be desired in some applications (col. 3, lines 6-28.) It is disclosed that coating portions of cardiovascular prostheses with a thin adherent film of silver provides protection from infection of the device. In some instances, the entire fabric member of the prosthetic device may not be coated with the silver, such as in areas of suture markings. In addition, in vivo experiments have shown excellent tissue ingrowth, without excessive thrombus formation. Minimal migration of silver into surrounding tissue may provide further anti-microbial protection. See column 4, lines 23-31.

Since Helmus discloses that the prepolymer mixture can be used to form various medical device such as artificial heart components and heart valves (col. 9, lines 52-68), the skilled artisan would have looked to the art, such as the Tweden patent, for

Art Unit: 1641

such specific medical devices that can be formed according to the Helmus teachings. It would have been obvious to one of ordinary skill in the art to combine the teachings of Helmus and Tweden regarding elements of a heart valve prosthesis that provide desirable therapeutic effects. In combining the teachings of Helmus and Tweden, it would have been obvious to the skilled artisan that the Tweden heart valve can be formed such that the body of the heart valve can be formed according to Helmus, that is including therapeutic materials, and can include a fabric overlayer as taught by Tweden, including a coating of a therapeutic agent which is specifically suggested by Tweden. The skilled artisan would have recognized that forming the heart valve from elements taught by Helmus and Tweden result in a heart valve with structural elements that provide therapeutic effects as taught by Helmus and Tweden. The skilled artisan would have reasonable expectation of success since Helmus teach that the disclosed invention can be used to form medical devices such as artificial heart components, vascular grafts, heart valves among other things (col. 9, lines 52-68), which the skilled artisan would recognize as encompassing annuloplasty rings, such as those disclosed by Tweden. (The Tweden annuloplasty ring meets the annular limitation recited by Applicant.) Moreover, the teachings of Helmus and Tweden are compatible with each other, since Helmus teach using a therapeutic agent in the polymer body and/or coating (col. 9, lines 38-49), and Tweden al. also teach that the underlying polymer body can be treated with a pre-clotting agent (col. 3, lines 6-28), and that the body may include a silver coating for protection from infection, or may not be coated with the silver (col. 4, lines 23-31), in which case, it is understood that the polymer body may

Art Unit: 1641

still include the coating of pre-clotting agent. Thus, it is clear to the skilled artisan that the device can be formed in various ways, including one in which the body is a polymer including a therapeutic agent (e.g., formed of the therapeutic agent, as taught by Helmus, or coated with the therapeutic agent, as taught by both Helmus and Tweden et al.), and overlaid with the fabric, for example, in portions of the polymer body, wherein the fabric may or may not include a silver coating for protection from infection, as taught by Tweden et al.

Allowable Subject Matter

Claims 21-36 and 41-69 are allowed.

The following is a statement of reasons for the indication of allowable subject matter. The primary reason for allowance is the inclusion of the limitations regarding a support formed from a polymer mixed with a steroidal agent or anti-inflammatory agent, forming a device that is suitable for use as a heart prosthesis. The Helmus et al. reference does not disclose or suggest that the therapeutic agent which comprises the support is a steroidal agent or an anti-inflammatory agent, and no such suggestion can be found in the prior art. It is noted that column 2, line 6, of the Helmus et al. reference, which was cited in the previous Office action, does not refer to the therapeutic agent that together with a polymer forms the *support*. Thus the rejection of the remaining claims have been withdrawn.

Response to Arguments

Applicant argues that the using the teachings of Helmus and Tweden, one would coat the fabric layer, not the support, body portion or polymer insert with the therapeutic agent. Regarding the claims reciting steroidal agent or anti-inflammatory agent being incorporated into the polymer support, rejection of these claims have been withdrawn.

Applicant further asserts that regarding claims 76 and 77, these claims recite “consisting of”, and notes that Helmus requires the use of an overlayer. Examiner emphasizes however that the Helmus overlayer is equivalent to Applicants overlayer, and with modification by Tweden, is formed of a fabric material. Examiner also notes that regarding Applicant’s argument that Tweden is limited to the use of metallic agents, Examiner disagrees since therapeutic coatings are disclosed by Tweden. Moreover, the silver coating is disclosed as being optional, not a requirement.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANN Y. LAM whose telephone number is (571)272-0822. The examiner can normally be reached on Mon.-Thurs. 9-7:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mark Shibuya can be reached on 571-272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ann Y. Lam/
Primary Examiner, Art Unit 1641